By Dhirendra Tripathi

Investing.com – Novavax stock (NASDAQ:) surged 6% in Thursday’s premarket trading after the company said it two-dose Covid-19 vaccine demonstrated “strong immune responses” against Omicron and other variants.

Six months later, a third dose showed an even more robust response.

Omicron is the predominant variant of Omicron in over 90 countries. This includes many in the U.S.A. According to some reports, Omicron is spreading twice as quickly as Delta (the variant that decimated India’s April-May attacks) and eventually the U.S.A and other parts of Europe. A consolation has been that new infections haven’t been reflected in increased hospitalizations.

Novavax found that adolescents responded two to four times faster than adults when exposed to all tested variants.

Company stated the findings will be peer-reviewed and published. It also said that Omicron vaccine development is well on its way to being manufactured in early January.

While Novavax has been late to the market in bringing its Covid-19 shots due to manufacturing challenges, the week saw the company’s proposed vaccine getting the European regulator’s approval for treating adults after WHO’s nod last week.

This shot was approved for use as an emergency medicine in Indonesia and Philippines. Similar approvals have been filed in the U.K. and U.A.E. in Australia, New Zealand and Canada. These clearances will be easier with the EU and WHO approvals.

If the company’s plans, as reported earlier, are on track, it should be filing with the Food and Drug Administration for approval in the U.S. in the next eight days.